Mutant p53 Protein as a Predictor of Survival in Endometrial Carcinoma

European Journal of Cancer

Volumn 32, Issue 4, 1996, Pages 598-602

  Strang, P ^a   Nordstrom B ^a   Nilsson, S ^a   Bergstrom R ^b   Tribukait, B ^c  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

DNA ploidy; Endometrial carcinoma; Nuclear grade; p53; Prognosis; Proliferation

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; ENDOMETRIUM CARCINOMA; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; CARCINOMA, ENDOMETRIOID; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; S PHASE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029988912     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00636-2     Document Type: Article

References (24)

1. Dödsorsaker 1991 (Causes of Deaths, 1991). Sveriges officiella statistik. Stockholm, Statitiska Centralbyrån, 1993.
2. Christopherson WM. The significance of the pathologic findings in endometrial cancer. Clin Obstet Gynaecol 1986, 13, 673-693.
3. DiSaia P, Creasman W, Boronow R, Blessing J. Risk factors and recurrent patterns in stage I endometrial cancer. Am J Obstet Gynecol 1985, 151, 1009-1015.
4. Hartmann L, Podratz K, Keeney G, et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 1994, 12, 64-69.
5. Henriksen R, Strang P, Wilander E, Bäckström T, Tribukait B, Öberg K. p53 expression in epithelial ovarian neoplasm: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol Oncol 1994, 53, 301-306.
6. Starzynska T, Bromley M, Ghosh A, Stern P. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 1992, 66, 558-562.
7. Ostrowski JL, Sawan A, Henry L, et al. p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J Pathol 1991, 164, 75-81.
8. Kur J, Winterford C, Harmon B. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994, 73, 2013-2016.
9. FIGO stages - 1988 revisions. Vulva, ovary, corpus. Gynecol Oncol 1989, 35, 125-127.
10. Rosenberg P, Risberg B, Simonsen E. The prognosis in early endometrial carcinoma. The importance of uterine papillary serous carcinoma (UPSC), Age, FIGO grade, and nuclear grade. Acta Obstet Gynecol Scand 1989, 68, 157-163.
11. Tribukait B. Flow cytometry in surgical pathology and cytology of tumours of the genito-urinary tract. In Koss LG, Coleman D, eds. Advances in Clinical Cytology, Vol. 2. Masson, New York, 1984, 163-189.
12. Castro J, Heiden T, Wang N, Tribukait B. Preparation of cell nuclei from fresh tissues for high-quality DNA flow cytometry. Cytometry 1993, 14, 793-804.
13. Heiden T, Strang P, Stendahl U, Tribukait B. Reproducibility of flow cytometric analyses in human malignancies. Anticancer Res 1990, 10, 49-54.
14. Stendahl U, Strang P, Wagenius G, Bergström R, Tribukiat B. Prognostic significance of proliferation in endometrial carcinoma. A multivariate analysis of clinical and flow cytometric variables. Int J Gynecol Pathol 1991, 10, 271-284.
15. Bur M, Perlman C, Edelmann L, Fey E, Rose P. p53 expression in neoplasms of the uterine corpus. Am J Clin Pathol 1992, 98, 81-87.
16. Tsuda H, Hirohashi S. Frequent occurrence of p53 gene mutations in uterine cancers at advanced clinical stage and with aggressive histological phenotypes. Jpn J Cancer Res 1992, 83, 1184-1191.
17. Kihana T, Hamada K, Inoue Y, et al. Mutation and allelic loss of the p53 gene in endometrial carcinoma. Cancer 1995, 76, 72-78.
18. Lipponen P. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer 1993, 53, 365-370.
19. Sorbe B, Risberg B, Thornthwaite J. Nuclear morphometry and DNA flow cytometry as prognostic methods for endometrial carcinoma. Int J Gynecol Cancer 1994, 4, 94-100.
20. Wagenius G, Bergström R, Strang P, et al. Prognostic significance of flow cytometric and clinical variables in endometrial adenocarcinoma stages I and II. Anticancer Res 1992, 12, 725-732.
21. Symonds DA. Prognostic value of pathologic features and DNA analysis in endometrial carcinoma. Gynecol Oncol 1990, 39, 272-276.
22. Lane DP. p53, guardian of the genome. Nature 1992, 358, 15-16.
23. Lukes A, Kohler M, Pieper C, et al. Multivariate analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer 1994, 73, 2380-2385.
24. Wynford-Thomas D. p53 in tumour pathology: can we trust immunohistochemistry? (Editorial) J Pathol 1992, 166, 329-330.